AstraZeneca and Russia will jointly develop COVID-19 vaccine
- Engineered Soybeans with Pig Protein: A Promising Alternative or Pandora’s Dish?
- Severe Fever with Thrombocytopenia Syndrome (SFTS): A Tick-Borne Threat with High Mortality
- Why Isolating Bananas Extends Their Shelf Life?
- This common vitamin benefits the brain and prevents cognitive decline
- New report reveals Nestlé adding sugar to infant formula sold in poor countries
- Did Cloud Seeding Unleash a Deluge in Dubai?
AstraZeneca and Russia will jointly develop COVID-19 vaccine
AstraZeneca and Russia will jointly develop COVID-19 vaccine. According to a report on the Forbes website, AstraZeneca said that it will work with Russia’s Gamalea Research Institute to develop a COVID-19 vaccine to test whether the combination of AstraZeneca’s AZD1222 vaccine and Russia’s Sputnik 5 is more effective.
The two vaccines are similar in composition and both use a special modified virus to deliver the vaccine. The Russian Sovereign Wealth Fund, which is responsible for investing in Sputnik-5, said that clinical trials will be launched at the end of 2020. If successful, Russia will jointly promote a joint vaccine. AstraZeneca also stated that it has begun recruiting volunteers for clinical trials.
Currently, the Sputnik-5 vaccine has been vaccinated in Russia, but it has not been widely accepted in European and American countries. AstraZeneca’s cooperation with it means a kind of recognition for it, but it cannot solve the mainstream scientific community’s concerns about the safety and effectiveness of the vaccine.
Interestingly, there are some doubts about the research data of these two vaccines. The vaccine developed in Russia is said to have a 90% preventive effect on the new coronavirus, but it has not yet been proven safe and effective through extensive clinical trials. The currently published data have not alleviated people’s concerns. The effectiveness of the AstraZeneca vaccine has also been questioned. It showed 90% and 62% preventive effects at two different doses, but 90% of the results were caused by accidents by the test operator, and the number of subjects Very limited. AstraZeneca plans to solve this problem through further clinical trials.
At the same time, the person in charge of Russian vaccines also announced that they are willing to share technology with Sanofi and GSK to help them develop vaccines. Earlier, the two announced that the vaccine program was postponed due to the substandard immune response of elderly subjects.
Disclaimer of medicaltrend.org
